Rhodes T, Lancaster K
Sociol Health Illn. 2021; 43(4):859-880.
PMID: 33942914
PMC: 8360046.
DOI: 10.1111/1467-9566.13263.
Norton B, Akiyama M, Arnsten J, Agyemang L, Heo M, Litwin A
Int J Drug Policy. 2021; 93:103135.
PMID: 33667826
PMC: 8725059.
DOI: 10.1016/j.drugpo.2021.103135.
Corcorran M, Tsui J, Scott J, Dombrowski J, Glick S
Drug Alcohol Depend. 2021; 220:108525.
PMID: 33461152
PMC: 7938869.
DOI: 10.1016/j.drugalcdep.2021.108525.
Uuskula A, Vickerman P, Raag M, Walker J, Paraskevis D, Eritsyan K
PLoS One. 2020; 15(10):e0240224.
PMID: 33035238
PMC: 7546465.
DOI: 10.1371/journal.pone.0240224.
Karimi S, Bayani A, Higgs P, Bayat A, Hemmat M, Ahounbar E
Subst Abuse Treat Prev Policy. 2020; 15(1):64.
PMID: 32831107
PMC: 7445934.
DOI: 10.1186/s13011-020-00306-1.
Motivations, facilitators and barriers to accessing hepatitis C treatment among people who inject drugs in two South African cities.
Versfeld A, McBride A, Scheibe A, Spearman C
Harm Reduct J. 2020; 17(1):39.
PMID: 32522210
PMC: 7288602.
DOI: 10.1186/s12954-020-00382-3.
Modeling Combination Hepatitis C Virus Treatment and Prevention Strategies in a Network of People Who Inject Drugs in the United States.
Zelenev A, Li J, Shea P, Hecht R, Altice F
Clin Infect Dis. 2020; 72(5):755-763.
PMID: 32060534
PMC: 7935393.
DOI: 10.1093/cid/ciaa142.
Addressing Hepatitis C in the American Incarcerated Population: Strategies for Nationwide Elimination.
Ocal S, Muir A
Curr HIV/AIDS Rep. 2020; 17(1):18-25.
PMID: 31933274
DOI: 10.1007/s11904-019-00476-z.
Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) - a natural experiment (protocol).
Hickman M, Dillon J, Elliott L, De Angelis D, Vickerman P, Foster G
BMJ Open. 2019; 9(9):e029538.
PMID: 31551376
PMC: 6773339.
DOI: 10.1136/bmjopen-2019-029538.
DOES IT WORK? -a randomized controlled trial to test the efficacy of HCV and HIV-related education on drug users in MMT, China.
Zhang J, Li Z, Zhang L, Wang J, Huang L, Zhan G
BMC Infect Dis. 2019; 19(1):774.
PMID: 31488064
PMC: 6727322.
DOI: 10.1186/s12879-019-4421-5.
Retrospective Study Demonstrating High Rates of Sustained Virologic Response After Treatment With Direct-Acting Antivirals Among American Indian/Alaskan Natives.
Mera J, Joshi K, Thornton K, Box T, Scott J, Sedillo M
Open Forum Infect Dis. 2019; 6(7):ofz128.
PMID: 31289725
PMC: 6610205.
DOI: 10.1093/ofid/ofz128.
Achievement of hepatitis C cascade of care milestones: a population-level analysis in Alberta, Canada.
ONeil C, Buss E, Plitt S, Osman M, Coffin C, Charlton C
Can J Public Health. 2019; 110(6):714-721.
PMID: 31222618
PMC: 6964571.
DOI: 10.17269/s41997-019-00234-z.
Risk Factors Associated with Linkage to Care among Suburban Hepatitis C-Positive Baby Boomers and Injection Drug Users.
Lier A, Smith K, Odekon K, Bronson S, Taub E, Tharakan M
Infect Dis Ther. 2019; 8(3):417-428.
PMID: 31129777
PMC: 6702540.
DOI: 10.1007/s40121-019-0249-y.
Evaluation of contingency management as a strategy to improve HCV linkage to care and treatment in persons attending needle and syringe programs: A pilot study.
Norton B, Bachhuber M, Singh R, Agyemang L, Arnsten J, Cunningham C
Int J Drug Policy. 2019; 69:1-7.
PMID: 31003171
PMC: 6704472.
DOI: 10.1016/j.drugpo.2019.02.009.
HIV, HBV and HCV in people who inject drugs and are placed on methadone maintenance therapy, Yangon, Myanmar.
Aye N, Oo M, Harries A, Mon M, Hone S, Oo H
Public Health Action. 2019; 8(4):202-210.
PMID: 30775281
PMC: 6361496.
DOI: 10.5588/pha.18.0050.
Evidence-based and guideline-concurrent responses to narratives deferring HCV treatment among people who inject drugs.
Childs E, Assoumou S, Biello K, Biancarelli D, Drainoni M, Edeza A
Harm Reduct J. 2019; 16(1):14.
PMID: 30744628
PMC: 6371610.
DOI: 10.1186/s12954-019-0286-6.
Associating conditional cash transfer to universal access to treatment could be the solution to the HCV epidemic among drug users (DUs).
Chossegros P, Di Nino F
Harm Reduct J. 2018; 15(1):63.
PMID: 30541570
PMC: 6292040.
DOI: 10.1186/s12954-018-0264-4.
Hepatitis C virus prevention and care for drug injectors: the French approach.
Delile J, de Ledinghen V, Jauffret-Roustide M, Roux P, Reiller B, Foucher J
Hepatol Med Policy. 2018; 3:7.
PMID: 30288330
PMC: 5987624.
DOI: 10.1186/s41124-018-0033-8.
A policy analysis exploring hepatitis C risk, prevention, testing, treatment and reinfection within Australia's prisons.
Lafferty L, Wild T, Rance J, Treloar C
Harm Reduct J. 2018; 15(1):39.
PMID: 30075728
PMC: 6091068.
DOI: 10.1186/s12954-018-0246-6.
'Hep C's like the common cold': understanding barriers along the HCV care continuum among young people who inject drugs.
Skeer M, Ladin K, Wilkins L, Landy D, Stopka T
Drug Alcohol Depend. 2018; 190:246-254.
PMID: 30071457
PMC: 6367928.
DOI: 10.1016/j.drugalcdep.2018.06.013.